These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 20865638)

  • 1. Complement in typical hemolytic uremic syndrome.
    Orth D; Würzner R
    Semin Thromb Hemost; 2010 Sep; 36(6):620-4. PubMed ID: 20865638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.
    Orth D; Khan AB; Naim A; Grif K; Brockmeyer J; Karch H; Joannidis M; Clark SJ; Day AJ; Fidanzi S; Stoiber H; Dierich MP; Zimmerhackl LB; Würzner R
    J Immunol; 2009 May; 182(10):6394-400. PubMed ID: 19414792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of typical (enteropathic) hemolytic uremic syndrome.
    Bitzan M; Schaefer F; Reymond D
    Semin Thromb Hemost; 2010 Sep; 36(6):594-610. PubMed ID: 20865636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.
    Poolpol K; Orth-Höller D; Speth C; Zipfel PF; Skerka C; de Córdoba SR; Brockmeyer J; Bielaszewska M; Würzner R
    Mol Immunol; 2014 Mar; 58(1):77-84. PubMed ID: 24317278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiology of typical hemolytic uremic syndrome.
    Karpman D; Sartz L; Johnson S
    Semin Thromb Hemost; 2010 Sep; 36(6):575-85. PubMed ID: 20865634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
    Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
    J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of complement in enterohemorrhagic Escherichia coli-Induced hemolytic uremic syndrome.
    Orth-Höller D; Würzner R
    Semin Thromb Hemost; 2014 Jun; 40(4):503-7. PubMed ID: 24799304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hemolytic uremic syndrome caused by enterohaemorrhagic Escherichia coli].
    Ibarra C; Goldstein J; Silberstein C; Zotta E; Belardo M; Repetto HA
    Arch Argent Pediatr; 2008 Oct; 106(5):435-42. PubMed ID: 19030644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome.
    Arvidsson I; Ståhl AL; Hedström MM; Kristoffersson AC; Rylander C; Westman JS; Storry JR; Olsson ML; Karpman D
    J Immunol; 2015 Mar; 194(5):2309-18. PubMed ID: 25637016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
    Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
    Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enterohemorrhagic Escherichia coli O26:H11-Associated Hemolytic Uremic Syndrome: Bacteriology and Clinical Presentation.
    Zimmerhackl LB; Rosales A; Hofer J; Riedl M; Jungraithmayr T; Mellmann A; Bielaszewska M; Karch H
    Semin Thromb Hemost; 2010 Sep; 36(6):586-93. PubMed ID: 20865635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of terminal complement activation in severe Shiga toxin-associated HUS - perfect example for a fast track from bench to bedside.
    Orth-Höller D; Riedl M; Würzner R
    EMBO Mol Med; 2011 Nov; 3(11):617-9. PubMed ID: 21954211
    [No Abstract]   [Full Text] [Related]  

  • 13. A clinical and bacteriological study of children suffering from haemolytic uraemic syndrome in Tucuman, Argentina.
    Miceli S; Jure MA; de Saab OA; de Castillo MC; Rojas S; de Holgado AP; de Nader OM
    Jpn J Infect Dis; 1999 Apr; 52(2):33-7. PubMed ID: 10816611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans.
    Friedrich AW; Zhang W; Bielaszewska M; Mellmann A; Köck R; Fruth A; Tschäpe H; Karch H
    Clin Infect Dis; 2007 Jul; 45(1):39-45. PubMed ID: 17554698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice.
    Zoja C; Locatelli M; Pagani C; Corna D; Zanchi C; Isermann B; Remuzzi G; Conway EM; Noris M
    J Immunol; 2012 Oct; 189(7):3661-8. PubMed ID: 22942429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hemolytic uremic syndrome in children of Mendoza, Argentina: association with Shiga toxin-producing Escherichia coli infection].
    Rivas M; Balbi L; Miliwebsky ES; García B; Tous MI; Leardini NA; Prieto MA; Chillemi GM; de Principi ME
    Medicina (B Aires); 1998; 58(1):1-7. PubMed ID: 9674201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).
    Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS
    Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hemolytic uremic syndrome in adults].
    Hertig A; Ridel C; Rondeau E
    Nephrol Ther; 2010 Jul; 6(4):258-71. PubMed ID: 20399168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between hemolytic uremic syndrome and verotoxin-producing strains of E. coli.
    Jure MA; de Saab OA; de Castillo MC; Sesma F; Miceli S; Zamora AM; de Ruiz Holgado AP; de Nader OM
    Rev Latinoam Microbiol; 1998; 40(1-2):1-8. PubMed ID: 10932728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement Gene Variants and Shiga Toxin-Producing
    Frémeaux-Bacchi V; Sellier-Leclerc AL; Vieira-Martins P; Limou S; Kwon T; Lahoche A; Novo R; Llanas B; Nobili F; Roussey G; Cailliez M; Ulinski T; Deschênes G; Alberti C; Weill FX; Mariani P; Loirat C
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):364-377. PubMed ID: 30674459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.